-
公开(公告)号：US20190010167A1
公开(公告)日：2019-01-10
申请号：US16064998
申请日：2016-12-21
发明人： David A. Claremon , Chenggou Dong , Yi Fan , Lanqi Jia , Suresh B. Singh , Shankar Venkatraman , Jing Yuan , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D495/04 , C07D513/04 , C07D471/10 , C07D487/10
摘要： The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
-
公开(公告)号：US20180222902A1
公开(公告)日：2018-08-09
申请号：US15709903
申请日：2017-09-20
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
-
公开(公告)号：US20170081327A1
公开(公告)日：2017-03-23
申请号：US15277836
申请日：2016-09-27
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
-
公开(公告)号：US20170007603A1
公开(公告)日：2017-01-12
申请号：US15204422
申请日：2016-07-07
发明人： Chengguo Dong , Yi Fan , Katerina Leftheris , Stephen D. Lotesta , Suresh B. Singh , Colin M. Tice , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： A61K31/506
CPC分类号： A61K31/506 , A61K31/4985 , C07D487/04 , C07F7/1804
摘要： Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
摘要翻译： 本文提供的是肝X受体调节剂的新化合物及其药学上可接受的盐。 还提供了包含本发明化合物和载体的组合物。 此外，进一步描述了本文的化合物的使用和与肝X受体相关的疾病或病症的治疗方法。
-
公开(公告)号：US20160122345A1
公开(公告)日：2016-05-05
申请号：US14933524
申请日：2015-11-05
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Linghang Zhuang
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
-
公开(公告)号：US20160122318A1
公开(公告)日：2016-05-05
申请号：US14933468
申请日：2015-11-05
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D401/12 , C07D405/14 , C07D413/14 , C07D209/44 , C07D403/12
CPC分类号： C07D401/12 , C07D209/44 , C07D403/12 , C07D405/14 , C07D413/14
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
摘要翻译： 提供了可用于治疗由RORγ介导的疾病和病症的式（I）的新化合物：其药学上可接受的盐及其药物组合物。 还提供了包含式（I）的新化合物的药物组合物及其用于治疗一种或多种炎症，代谢，自身免疫和其它疾病或病症的方法。
-
公开(公告)号：US20150218160A1
公开(公告)日：2015-08-06
申请号：US14609798
申请日：2015-01-30
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Zhijie Liu , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , C07D519/00
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
摘要翻译： 提供了可用于治疗由RORγ介导的疾病和病症的式（I）的新化合物：其药学上可接受的盐及其药物组合物。 还提供了包含式（I）的新化合物的药物组合物及其用于治疗一种或多种炎症，代谢，自身免疫和其它疾病或病症的方法。
-
公开(公告)号：US20190144459A1
公开(公告)日：2019-05-16
申请号：US16308739
申请日：2017-06-08
发明人： Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Stephen D. Lotesta , Andrew Marcus , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Jing Yuan , Yajun Zheng , Linghang Zhuang , Stephan D. Parent , Travis L. Houston
IPC分类号： C07D487/10 , A61P35/02 , C07D471/10 , C07F9/6561 , C07D491/107 , C07D403/04 , C07D403/14
CPC分类号： C07D487/10 , A61P35/02 , C07B2200/13 , C07D403/04 , C07D403/14 , C07D405/14 , C07D471/10 , C07D491/10 , C07D491/107 , C07F9/6561
摘要： The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
-
公开(公告)号：US10144715B2
公开(公告)日：2018-12-04
申请号：US15502356
申请日：2015-08-04
发明人： David A. Claremon , Chengguo Dong , Yi Fan , Katerina Leftheris , Stephen D. Lotesta , Suresh B. Singh , Colin M. Tice , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D241/04 , C07D403/04 , C07D413/14 , C07D401/04 , C07D401/06 , C07D403/14 , C07D405/06 , C07D413/04 , C07D417/04 , C07D417/14 , C07D497/04 , C07D513/04
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of Formula (I) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer's disease, dermatitis, dyslipidemia, cancer and other diseases or disorders.
-
公开(公告)号：US20170260180A1
公开(公告)日：2017-09-14
申请号：US15455481
申请日：2017-03-10
发明人： David A. Claremon , Lawrence Wayne Dillard , Chengguo Dong , Yi Fan , Lanqi Jia , Zhijie Liu , Stephen D. Lotesta , Andrew Marcus , Suresh B. Singh , Colin M. Tice , Jing Yuan , Wei Zhao , Yajun Zheng , Linghang Zhuang
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.043 秒)
